BJMO - 2019, issue Special, march 2019
Brian Chapin, MD
Radical treatment of the primary tumour in patients with metastatic prostate cancer (PCa) has been debated for several decades. The concept of combining systemic therapy with primary tumour cytoreduction has been attempted in different malignancies and recent data also suggest a potential benefit of this strategy in PCa. This include an improved local tumour control, but there are also data indicating that local treatment might alter the natural course of metastatic disease. In his presentation, Prof. dr. Brian Chapin (MD Anderson Cancer Centre, Houston TX, United States) discussed the rationale, the available data and ongoing trials regarding local treatment in patients with (oligo) metastatic PCa.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
